Multiple sclerosis: (Q62065048)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Mathilde Kouwenhoven

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Sten Fredrikson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

N Teleshova

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

M Pashenkov

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

H Link

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 August 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuroimmunology

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

236-243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

Measurement of serum cytokines

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

The effect of interferon beta-1b on lymphocyte-endothelial cell adhesion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Changes in plasma cytokines induced by interferon-beta1a treatment in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Changes of serum sICAM-1 and MMP-9 induced by rIFN -1b treatment in relapsing-remitting MS

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Metalloproteinases and their tissue inhibitors in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900281-2

7 January 2021

10.1016/S0165-5728(00)00281-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10900359%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference